Intelligence for Dermatology Specialists

Dermatology clinical trials
recruiting in the United States

Up-to-date overview of clinical trials in atopic dermatitis, psoriasis, alopecia, hidradenitis suppurativa and other dermatology indications recruiting patients in the United States — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centers.

Active trials

891

US sites

Indications covered

BR trials

Loading map…

85 studies found

N/DAtopic DermatitisEczemaUS 1 site in the US

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

National Human Genome Research Institute (NHGRI)

📍 Bethesda👥 530 participants

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Dermatite AtopicaPele Saudavel VoluntariosUS 1 site in the US

Effects of Treatments on Atopic Dermatitis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

📍 Bethesda👥 130 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriasisArtrite PsoriasicaDoenca de CrohnUS 1 site in the US

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

University of California, San Diego

📍 La Jolla👥 200 participants📅 Completion: 2030-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriase em PlacasUS 1 site in the US

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 30 participants📅 Completion: 2019-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoríase em PlacasUS 1 site in the US

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 30 participants📅 Completion: 2019-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisAdverse Pregnancy OutcomesUS 1 site in the US

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Regeneron Pharmaceuticals

📍 Boston👥 3930 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Plaque PsoriasisUS 3 sites in the US

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Bausch Health Americas, Inc.

📍 Doral, Miami, Thousand Oaks👥 45 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Plaque PsoriasisUS 1 site in the US

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Wright State University

📍 Fairborn👥 24 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisPsoriasisHealthy ControlUS 1 site in the US

Skin Microbial Ecology in Atopic Dermatitis

University of Rochester

📍 Rochester👥 240 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoríase em PlacasUS 1 site in the US

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 25 participants📅 Completion: 2020-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoriase em PlacasUS 1 site in the US

Taltz in Combination With Enstilar for Psoriasis

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 25 participants📅 Completion: 2021-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Boston Children's Hospital

📍 Boston👥 111 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DColite UlcerativaDoenca de CrohnArtrite ReumatoideUS 1 site in the US

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Terrence A Barrett

📍 Lexington👥 60 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DMelanomaDoenca Inflamatoria IntestinalArtrite ReumatoideUS 1 site in the US

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

M.D. Anderson Cancer Center

📍 Houston👥 125 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DPlaque PsoriasisArtrite PsorialticaDoenca de CrohnUS 1 site in the US

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

AbbVie

📍 Morrisville👥 818 participants📅 Completion: 2032-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DPrimary ImmunodeficiencyPsoriaseDermatite AtopicaUS 1 site in the US

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Bethesda👥 300 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4PsoriaseUS 3 sites in the US

Multi-Center PAMPA Study

NYU Langone Health

📍 Boston, New York, Rochester👥 176 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisDisturbio do SonoUS 1 site in the US

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Northwestern University

📍 Chicago👥 40 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

Ethnic Differences in Mechanisms of Action of Dupilumab

University of Michigan

📍 Ann Arbor👥 30 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

Dupixent and Narrowband UVB for Atopic Dermatitis

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 40 participants📅 Completion: 2024-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationAllergiesAlpha Gal SyndromeUS 1 site in the US

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sanguine Biosciences

📍 Waltham👥 20000 participants📅 Completion: 2025-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DArtrite PsoriaticaUS 1 site in the US

Stronger Together Psoriatic Arthritis Wellness Study

Global Healthy Living Foundation

📍 Upper Nyack👥 100 participants📅 Completion: 2026-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 14 sites in the US

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

University of Pennsylvania

📍 Blue Ash, Colleyville, Crossville, El Paso, Lilburn, Loxahatchee Groves, New York, Omaha👥 63 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Pfizer

📍 New York👥 400 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

Molecular Signatures of Cutaneous Dupilumab Response

University of California, San Francisco

📍 San Francisco👥 15 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoriase do Couro CabeludoUS 1 site in the US

Immune Spatial Features of Guselkumab Cutaneous Response

University of California, San Francisco

📍 San Francisco👥 10 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoriase VulgarisUS 1 site in the US

Correction of Psoriatic T Cell Signatures by Deucravacitinib

University of California, San Francisco

📍 San Francisco👥 25 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DArtrite ReumatoideArtrite PsorialticaPsoriaseUS 1 site in the US

IMPACT - AndHealth Autoimmune Research Registry

AndHealth

📍 Columbus👥 2500 participants📅 Completion: 2023-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

University of California, San Diego

📍 La Jolla👥 900 participants📅 Completion: 2034-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 43 sites in the US

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Pfizer

📍 Birmingham, Chickasha, Clarkston, Dallas, Doral, East Syracuse, Frisco, Hunt Valley👥 340 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 1 site in the US

Cardamom and Topical Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Bethesda👥 120 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Juvenile Psoriatic ArthritisUS 11 sites in the US

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

AbbVie

📍 Austin, Chapel Hill, Cleveland, Hollywood, Indianapolis, Little Rock, Miami, Minneapolis👥 40 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DGeneralized Pustular PsoriasisUS 1 site in the US

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

CorEvitas

📍 Waltham👥 200 participants📅 Completion: 2099-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Registry for Systemic Eczema Treatments

Johns Hopkins University

📍 Baltimore👥 400 participants📅 Completion: 2030-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

CorEvitas

📍 Waltham👥 1500 participants📅 Completion: 2099-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Dermatite AtopicaUS 43 sites in the US

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Sanofi

📍 Albuquerque, Ann Arbor, Arlington, Bellaire, Birmingham, Bowling Green, Boynton Beach, Charleston👥 636 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Topical Treatment for Atopic Dermatitis

Wake Forest University Health Sciences

📍 Winston-Salem👥 30 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisGravidezUS 1 site in the US

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Incyte Corporation

📍 Morrisville👥 958 participants📅 Completion: 2032-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlergia AlimentarAlergia Alimentar Com Dermatite AtopicaDermatite AtopicaUS 1 site in the US

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

University of Michigan

📍 Ann Arbor👥 200 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Atopic DermatitisUS 14 sites in the US

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

LEO Pharma

📍 Birmingham, Charleston, Jacksonville, Macon, Miami, Norfolk, North Little Rock, Palo Alto👥 195 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DArtrite ReumatoideArtrite PsoriaticaEspondilite AnquilosanteUS 1 site in the US

Rheumatology Diet Study

University of Central Florida

📍 Orlando👥 500 participants📅 Completion: 2025-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

University Hospitals Cleveland Medical Center

📍 Cleveland👥 36 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Artrite PsoriaticaEspondiloartrite AxialUS 3 sites in the US

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

CARE ARTHRITIS LTD.

📍 Cleveland, Philadelphia, Portland👥 100 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Atopic DermatitisUS 26 sites in the US

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

AbbVie

📍 Arlington, Boise, Bowling Green, Canal Winchester, Charleston, Chicago, Coral Gables, El Paso👥 675 participants📅 Completion: 2030-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DDermatite AtopicaPruridoUS 1 site in the US

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

Nexgen Dermatologics, Inc.

📍 Boynton Beach👥 60 participants📅 Completion: 2024-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisUS 7 sites in the US

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Chicago, Cincinnati, Denver, Madison, New York, Rochester, San Diego👥 86 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Healthy ParticipantsAtopic DermatitisUS 1 site in the US

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Pfizer

📍 Anaheim👥 119 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

University of California, Davis

📍 Sacramento👥 5 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Doenca de CrohnColite UlcerativaArtrite PsoriaticaUS 5 sites in the US

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Janssen Research & Development, LLC

📍 Atlanta, Cincinnati, Indianapolis, Salt Lake City👥 196 participants📅 Completion: 2031-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 21 sites in the US

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Takeda

📍 Baltimore, Boca Raton, Bowling Green, Charlotte, Cleveland, Covina, Duncansville, Fort Worth👥 600 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Dermatite AtopicaUS 10 sites in the US

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Pfizer

📍 Birmingham, Charleston, Greenville, Indianapolis, Jacksonville, North Little Rock, San Antonio, San Diego👥 150 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 21 sites in the US

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

Janssen Research & Development, LLC

📍 Albuquerque, Allen, Charlotte, Clearwater, Dallas, DeBary, Duncansville, Eagan👥 750 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisUS 2 sites in the US

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Bambusa Therapeutics

📍 New York, The Bronx👥 237 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoríase em PlacasObesidade ou SobrepesoUS 40 sites in the US

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Eli Lilly and Company

📍 Ann Arbor, Bay City, Bellaire, Bellevue, Boardman, Bowling Green, Brighton, Burien👥 200 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Artrite PsoriaticaSobrepeso ou ObesidadeUS 53 sites in the US

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Eli Lilly and Company

📍 Apple Valley, Avondale, Chandler, Chicago, Colleyville, Covina, Cumberland, Flagstaff👥 200 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Plaque PsoriasisPsoriatic ArthritisAxial SpondyloarthritisUS 6 sites in the US

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

UCB Biopharma SRL

📍 Boston, Chapel Hill, Durham, Milwaukee, Santa Monica, South Miami👥 20 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Pfizer

📍 New York👥 150 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

Johann E Gudjonsson MD PhD

📍 Folsom👥 48 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 22 sites in the US

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Novartis Pharmaceuticals

📍 Arlington, Atlanta, Birmingham, Brighton, Brooklyn, Cypress, Dallas, Fort Smith👥 224 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Psoríase em PlacasUS 25 sites in the US

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Bristol-Myers Squibb

📍 Atlanta, Canton, Detroit, Fremont, Goodlettsville, Indianapolis, Las Vegas, Lorain👥 366 participants📅 Completion: 2029-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisPsoriase em PlacasUS 2 sites in the US

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

LAPIX Therapeutics Inc.

📍 Dallas, Fargo👥 48 participants📅 Completion: 2026-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 2 sites in the US

Sodium in the Skin and Atopic Dermatitis

University of California, San Francisco

📍 San Francisco👥 90 participants📅 Completion: 2028-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

A Study to Assess Deucravacitinib Safety in Pregnancy

Bristol-Myers Squibb

📍 La Jolla👥 900 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Plaque PsoriasisUS 1 site in the US

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

Ascletis Pharma (China) Co., Limited

📍 Miami👥 94 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 16 sites in the US

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Inmagene LLC

📍 Anderson, Burien, Charlotte, Columbus, Fargo, Kew Gardens, Lancaster, Los Angeles👥 405 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 48 sites in the US

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Bluefin Biomedicine, Inc.

📍 Auburn Hills, Boardman, Boca Raton, Brighton, Burien, Canton, Charlotte, Coral Gables👥 225 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DRheumatoid ArthritisSjogren SyndromeSystemic Lupus ErythematosusUS 1 site in the US

Creating Health Course Study for People With Rheumatological Conditions

Terry L. Wahls

📍 Iowa City👥 200 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 3 sites in the US

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Hoffmann-La Roche

📍 Alpharetta, Camp Hill, Troy👥 120 participants📅 Completion: 2033-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Plaque PsoriasisUS 10 sites in the US

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

Takeda

📍 Canton, Charleston, Chula Vista, Fairborn, Fountain Valley, Hialeah, Mayfield Heights, Milwaukee👥 110 participants📅 Completion: 2033-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Hiper Ige Sindrome Stat3Lupus Eritematoso SistemicoDermatite AtopicaUS 1 site in the US

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Bethesda👥 20 participants📅 Completion: 2030-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Atopic DermatitisUS 36 sites in the US

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Organon and Co

📍 Auburn Hills, Bellaire, Birmingham, Boca Raton, Bowling Green, Bryant, Castle Rock, Chapel Hill👥 180 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 20 sites in the US

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

UCB Biopharma SRL

📍 Boca Raton, Bowling Green, Chicago, Dallas, Frisco, Miami, New Albany, New York👥 160 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 12 sites in the US

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Takeda

📍 Baytown, Bellaire, Denver, Fountain Valley, Hagerstown, Hialeah, Houston, Jackson👥 1182 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Artrite PsoriaticaEspondiloartrite AxialUS 30 sites in the US

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

UCB Biopharma SRL

📍 Albuquerque, Apple Valley, Baytown, Beckley, Bellevue, Chicago, Colleyville, Covina👥 392 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Plaque PsoriasisUS 20 sites in the US

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics, Inc.

📍 Chapel Hill, Cleveland, Frisco, Houston, Kew Gardens, Los Angeles, Mason, Miami👥 160 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 43 sites in the US

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Sanofi

📍 Albuquerque, Ann Arbor, Auburn Hills, Bakersfield, Bay City, Birmingham, Bolivar, Bountiful👥 1000 participants📅 Completion: 2034-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Artrite PsoriasicaUS 16 sites in the US

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

Janssen Research & Development, LLC

📍 Albuquerque, Allen, Charlotte, Cutler Bay, Evansville, Huntington Beach, Marietta, Middleburg Heights👥 240 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DGut MicrobiomeEczemaUS 1 site in the US

Flourish: Exploring the Early Infant Gut Microbiome

Seeding Inc

📍 Austin👥 250 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 1 site in the US

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Corvus Pharmaceuticals, Inc.

📍 South San Francisco👥 200 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Psoríase em PlacasUS 16 sites in the US

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Oruka Therapeutics, Inc.

📍 Boston, Bowling Green, Cromwell, Detroit, Fountain Valley, Los Angeles, Miami, New York👥 240 participants📅 Completion: 2030-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisEczemaUS 1 site in the US

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Arcutis Biotherapeutics, Inc.

📍 Fair Lawn👥 125 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

Sirt3 LLC

📍 Englewood👥 100 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Hidradenite SupurativaUS 78 sites in the US

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

AbbVie

📍 Arlington, Bellaire, Birmingham, Boca Raton, Boise, Boston, Bountiful, Bowling Green👥 1328 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alopecia AreataUS 29 sites in the US

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

AbbVie

📍 Arlington, Bellaire, Boca Raton, Cedar Park, Clarkston, Cleveland, Dallas, Fountain Valley👥 1500 participants📅 Completion: 2030-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Psoríase em PlacasUS 90 sites in the US

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Bristol-Myers Squibb

📍 Alpharetta, Anderson, Arlington, Auburn Hills, Boca Raton, Bowling Green, Brighton, Camp Hill👥 3040 participants📅 Completion: 2031-01

View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Dermatology clinical trialsrecruiting in the United States

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Effects of Treatments on Atopic Dermatitis

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Skin Microbial Ecology in Atopic Dermatitis

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Taltz in Combination With Enstilar for Psoriasis

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Multi-Center PAMPA Study

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Ethnic Differences in Mechanisms of Action of Dupilumab

Dupixent and Narrowband UVB for Atopic Dermatitis

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Stronger Together Psoriatic Arthritis Wellness Study

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Molecular Signatures of Cutaneous Dupilumab Response

Immune Spatial Features of Guselkumab Cutaneous Response

Correction of Psoriatic T Cell Signatures by Deucravacitinib

IMPACT - AndHealth Autoimmune Research Registry

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Cardamom and Topical Roseomonas in Atopic Dermatitis

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Registry for Systemic Eczema Treatments

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Topical Treatment for Atopic Dermatitis

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Rheumatology Diet Study

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Sodium in the Skin and Atopic Dermatitis

A Study to Assess Deucravacitinib Safety in Pregnancy

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Creating Health Course Study for People With Rheumatological Conditions

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

Flourish: Exploring the Early Infant Gut Microbiome

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Dermatology clinical trials
recruiting in the United States